Due to health issues, this site is no longer maintained and will be shut down shortly.

LN:SLN Silence Therapeutics Plc

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.This company has ADRs that trade in the U.S. as the symbol SLN.

535.00 GBP
As of 11/29/2021

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  United Kingdom
IPO date:  07/19/1995
Stock exchange:    London Stock Exchange
Exchange country:   United Kingdom
Market cap:   480,348,160 GBP
Current dividend yield:   0.00%
Sedol:      B9GTXM6

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy